# Oxylanthanum PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/oxylanthanum

> Oxylanthanum, sponsored by Unicycive Therapeutics, Inc. (UNCY), received a complete response letter from the FDA; the decision is dated October 28, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is oxylanthanum FDA approved?

Not as of November 16, 2026. Oxylanthanum, sponsored by Unicycive Therapeutics, Inc. (UNCY), received a complete response letter from the FDA; the decision is dated October 28, 2025. SEC Form 10-Q: "On October 28, 2025, we announced an update from our meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of our New Drug Application (NDA) for Oxylanthanum carbonate (OLC) following receipt of a CRL on June 30, 2025." [Calendar and source filings](https://sec-api.dev/pdufa/oxylanthanum)

Source: SEC Form 10-Q, accession 0001213900-26-088013, https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm (retrieved 2026-11-12). Last confirmed 2026-08-12. Cite: https://sec-api.dev/pdufa/oxylanthanum#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | oxylanthanum |
| Codes |  |
| Sponsor | Unicycive Therapeutics, Inc. (UNCY) https://sec-api.dev/companies/uncy/catalysts |
| Indications | [hyperphosphatemia in patients with chronic kidney disease](https://sec-api.dev/indications/hyperphosphatemia-in-patients-with-chronic-kidney-disease), [kidney disease](https://sec-api.dev/indications/kidney-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 3, 2024: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: hyperphosphatemia in patients with chronic kidney disease.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0001213900-24-097118): "On September 3, 2024, we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." https://www.sec.gov/Archives/edgar/data/1766140/000121390024097118/ea0220114-10q_unicycive.htm

### November 11, 2024: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0001213900-24-097118): "On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025." https://www.sec.gov/Archives/edgar/data/1766140/000121390024097118/ea0220114-10q_unicycive.htm

### June 28, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-03-31.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-026270): "- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025" https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea023632401ex99-1_unicycive.htm
- SEC Form 10-Q (accession 0001213900-24-097118): "On November 11, 2024, we announced that the FDA has accepted the NDA for OLC and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025." https://www.sec.gov/Archives/edgar/data/1766140/000121390024097118/ea0220114-10q_unicycive.htm
- SEC Form 8-K (accession 0001213900-24-096104): "issued a press release announcing that the U.S. Food and Drug Administration has accepted the New Drug Application for Oxylanthanum Carbonate (OLC) and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025." https://www.sec.gov/Archives/edgar/data/1766140/000121390024096104/ea0220621-8k_unicycive.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-059303): "Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis" https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm

### June 30, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: Hyperphosphatemia in Patients with Chronic Kidney Disease.
- First seen 2025-06-30, last confirmed 2026-03-30.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-059303): "Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis" https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-059303): "Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a CRL for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." https://www.sec.gov/Archives/edgar/data/1766140/000121390025059303/ea024746901ex99-1_unicycive.htm
- SEC Form 10-K (accession 0001213900-26-035903): "In June 2025, the FDA issued us a Complete Response Letter (CRL) notifying us that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection." https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm

### late 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: half.
- First seen 2025-05-14, last confirmed 2025-05-14.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-042967): "- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025" https://www.sec.gov/Archives/edgar/data/1766140/000121390025042967/ea024208101ex99-1_unicycive.htm

### October 28, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: kidney disease.
- First seen 2025-10-28, last confirmed 2026-08-12.
- SEC Form 10-Q (accession 0001213900-26-088013): "On October 28, 2025, we announced an update from our meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of our New Drug Application (NDA) for Oxylanthanum carbonate (OLC) following receipt of a CRL on June 30, 2025." https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm
- SEC Form 10-Q (accession 0001213900-26-054708): "On October 28, 2025,we announced an update from our meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of our New Drug Application (NDA) for Oxylanthanum carbonate (OLC) following receipt of a CRL on June 30, 2025." https://www.sec.gov/Archives/edgar/data/1766140/000121390026054708/ea0289336-10q_unicycive.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-102790): "Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or Unicycive), today announced an update from its meeting with the U.S. Food and Drug Administration (FDA) and timing of the resubmission of its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) following receipt of a Complete Response Letter (CRL)" https://www.sec.gov/Archives/edgar/data/1766140/000121390025102790/ea026272301ex99-1_unicycive.htm

### Dec 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-08-12, last confirmed 2026-08-12.
- SEC Form 10-Q (accession 0001213900-26-088013): "Following receipt of the official meeting minutes from the Type A meeting and engaging in discussions with our third-party manufacturing vendor, we resubmitted our NDA to the FDA in December 2025." https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm

### June 29, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-03-30, last confirmed 2026-08-12.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-054736): "Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026" https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm
- SEC Form 10-Q (accession 0001213900-26-088013): "In January 2026, the FDA accepted the resubmission of the NDA for OLC, deeming the resubmission to be a Class II complete response which has a six-month review period from the date of resubmission, and set a PDUFA target action date of June 29, 2026." https://www.sec.gov/Archives/edgar/data/1766140/000121390026088013/ea0300450-10q_unicycive.htm
- SEC Form 10-Q (accession 0001213900-26-054708): "In January 2026, the FDA accepted the resubmission of the NDA for OLC, deeming the resubmission to be a Class II complete response which has a six-month review period from the date of resubmission, and set a PDUFA target action date of June 29, 2026." https://www.sec.gov/Archives/edgar/data/1766140/000121390026054708/ea0289336-10q_unicycive.htm
- SEC Form 10-K (accession 0001213900-26-035903): "In January 2026, the FDA accepted the resubmission of the NDA for OLC, deeming the resubmission to be a Class II complete response which has a six-month review period from the date of resubmission, and set a PDUFA) target action date of June 29, 2026." https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm
- SEC Form 10-K (accession 0001213900-26-035903): "We resubmitted an NDA in December 2025 and the FDA set a PDUFA target action date of June 29, 2026." https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm
- SEC Form 10-K (accession 0001213900-26-035903): "January 2026, the FDA accepted the resubmission of the NDA for OLC, deeming the resubmission to be a Class II complete response which has a six-month review period from the date of resubmission, and set a PDUFA target action date of June 29, 2026" https://www.sec.gov/Archives/edgar/data/1766140/000121390026035903/ea0281982-10k_unicycive.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-054736): "The FDA set a PDUFA target action date of June 29, 2026." https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea029027701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-035961): "Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026" https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/ea028394201ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-035961): "The FDA set a PDUFA target action date of June 29, 2026." https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/ea028394201ex99-1.htm

Calendar months: [June 2026](https://sec-api.dev/fda-calendar/2026-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/oxylanthanum.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Oxylanthanum PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/oxylanthanum

```bibtex
@misc{secapidev_pdufa_oxylanthanum_20261116,
  title        = {Oxylanthanum PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/oxylanthanum}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_oxylanthanum_20261116","title":"Oxylanthanum PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/oxylanthanum","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
